BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

Asieris Announces Breakthrough Non-Surgical Treatment for Cervical High-Grade Squamous Intraepithelial Lesion

Asieris Pharmaceuticals (Stock Code: 688176.SH), a trailblazer in the global biopharmaceutical industry with a focus on genitourinary tumors and related di...

March 19, 2024 | News

KeChow Pharma's Tunlametinib Receives Historic Approval in China for Advanced Melanoma Treatment

KeChow Pharma, a commercial-stage pharmaceutical company focused on developing and commercializing differentiated small molecule therapeutics for cancer, t...

March 19, 2024 | News

Revvity Launches Revolutionary Newborn Sequencing Workflow to Advance Rare Disease Diagnosis

Revvity, Inc., a pioneering force in genomic sequencing technology, has announced the launch of a groundbreaking "sample-to-answer" workflow tailored speci...

March 18, 2024 | News

CStone's Sugemalimab Granted Historic Approval in China for Gastric Cancer Treatment

CStone Pharmaceuticals has achieved a significant milestone with the approval of sugemalimab (Cejemly®) by the National Medical Products Administration...

March 18, 2024 | News

BeiGene's TEVIMBRA Wins FDA Nod for Advanced Esophageal Cancer Post-Chemotherapy

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has app...

March 15, 2024 | News

Almirall and Eloxx Pharmaceuticals Forge Exclusive Global License Agreement for Rare Disease Treatment ZKN-013

Almirall, S.A. (BME:ALM), a global biopharmaceutical company, and Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a clinical-stage biopharmaceutical innovator, ha...

March 14, 2024 | News

TiumBio Advances TU2218 in Phase 2a Trial with Pembrolizumab for Three Cancer Types

TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizumab TU2218 demonstrated a favorable safety and a synerget...

March 12, 2024 | News

Eisai Boosts Support for Alzheimer's Diagnosis with $15 Million Investment in C2N Diagnostics

Eisai Co., Ltd. announced a significant step forward in the fight against Alzheimer's disease (AD) today, with its U.S. subsidiary Eisai Inc. committing up...

March 07, 2024 | News

BioGate Announces Breakthrough in Pancreatic Cancer Treatment with New Drug BGX

Under the leadership of Dr. Frank Huang, Chairman and CEO, BioGate disclosed that their in-house research and development team has engineered BGX by integr...

March 07, 2024 | News

Sunbird Bio Advances Alzheimer's Diagnosis with APEX Blood Test, Matching PET Scan Accuracy

Sunbird Bio, a biotechnology company developing proprietary protein- and blood-based technologies to improve diagnosis and treatment of neurological disord...

March 06, 2024 | News

Innovent Biologics and AnHeart Therapeutics Secure Second NDA Acceptance for Groundbreaking Lung Cancer Treatment in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...